Citations (81)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (15)
Fatemeh Rahimi Haji Abadi, Fariba Tadayon, Mohammad Saber Tehrani & Homayon Ahmad Panahi. (2023) Synthesis and characterization of the photoresponsive and thermoresponsive molecularly imprinted polymer with a novel functional monomer for controlled release of 4-Aminopyridine. International Journal of Polymeric Materials and Polymeric Biomaterials 72:6, pages 425-432.
Read now
Read now
Angelo Bellinvia, Emilio Portaccio & Maria Pia Amato. (2023) Current advances in the pharmacological prevention and management of cognitive dysfunction in multiple sclerosis. Expert Opinion on Pharmacotherapy 24:4, pages 435-451.
Read now
Read now
Maria Pia Amato, Elio Prestipino & Angelo Bellinvia. (2019) Identifying risk factors for cognitive issues in multiple sclerosis. Expert Review of Neurotherapeutics 19:4, pages 333-347.
Read now
Read now
Nahid Ghebleh Zadeh, Gholamhassan Vaezi, Azam Bakhtiarian, Zahra Mousavi, Abdolhossein Shiravi & Vahid Nikoui. (2019) The potassium channel blocker, dalfampridine diminishes ouabain-induced arrhythmia in isolated rat atria. Archives of Physiology and Biochemistry 125:1, pages 25-29.
Read now
Read now
Jessica F. Baird, Brian M. Sandroff & Robert W. Motl. (2018) Therapies for mobility disability in persons with multiple sclerosis. Expert Review of Neurotherapeutics 18:6, pages 493-502.
Read now
Read now
Miriam Alvarez-Payero, Candelas Valeiras-Muñoz, Susana Lion-Vázquez, Guadalupe Piñeiro-Corrales, Delicias Muñoz-García & Luciana Midaglia. (2017) Experience with fampridine in clinical practice: analysis of a possible marker of clinical response. International Journal of Neuroscience 127:10, pages 915-922.
Read now
Read now
Michele Jara, Thomas Aquilina, Peter Aupperle & Adrian L Rabinowicz. (2015) Safety profile of dalfampridine extended release in multiple sclerosis: 5-year postmarketing experience in the United States. Drug, Healthcare and Patient Safety 7, pages 169-174.
Read now
Read now
Alessandra Lugaresi. (2015) Pharmacology and clinical efficacy of dalfampridine for treating multiple sclerosis. Expert Opinion on Drug Metabolism & Toxicology 11:2, pages 295-306.
Read now
Read now
Michele Jara, Graham Barker & Herbert R Henney$suffix/text()$suffix/text(). (2013) Dalfampridine extended release tablets: 1 year of postmarketing safety experience in the US. Neuropsychiatric Disease and Treatment 9, pages 365-370.
Read now
Read now
Anthony Caggiano & Andrew Blight. (2013) In vitro evaluation of the effects of 4-aminopyridine on cytochrome P450 enzymes. Journal of Drug Assessment 2:1, pages 106-116.
Read now
Read now
Anthony Caggiano, Andrew Blight & Tom J. Parry. (2013) Identification of metabolites of dalfampridine (4-aminopyridine) in dog and rat. Journal of Drug Assessment 2:1, pages 72-80.
Read now
Read now
Anthony Caggiano, Andrew Blight & Tom J. Parry. (2013) Effects of dalfampridine and its metabolites on cloned human potassium channels Kv 1.1, Kv 1.2, and Kv 1.4 expressed in human embryonic kidney cells. Journal of Drug Assessment 2:1, pages 58-66.
Read now
Read now
Herbert R Henney$suffix/text()$suffix/text() & Andrew R Blight. (2012) Walking impairment in patients with multiple sclerosis – a new therapeutic approach and clinical potential of dalfampridine extended release tablets. Degenerative Neurological and Neuromuscular Disease 2, pages 53-64.
Read now
Read now
Oscar Fernandez, Thomas Berger, Hans-Peter Hartung & Norman Putzki. (2012) Historical overview of the rationale for the pharmacological use of prolonged-release fampridine in multiple sclerosis. Expert Review of Clinical Pharmacology 5:6, pages 649-665.
Read now
Read now
Sheryl R. Haut, E. Jay Bienen & Aaron Miller. (2012) Clinical overview of the seizure risk of dalfampridine
. Expert Opinion on Drug Safety 11:4, pages 651-657.
Read now
Read now
Articles from other publishers (66)
Afshin Babazadeh, Stephanie L. Rayner, Albert Lee & Roger S. Chung. (2023) TDP-43 as a therapeutic target in neurodegenerative diseases: Focusing on motor neuron disease and frontotemporal dementia. Ageing Research Reviews 92, pages 102085.
Crossref
Crossref
Sahar Ghorbanpour, Sarvenaz Rahimibarghani, Setareh Rohani, Mohsen Rastkar & Mahsa Ghajarzadeh. (2023) Fampridine for gait imbalance in patients with multiple sclerosis (MS): a systematic review and meta-analysis. Neurological Sciences 44:9, pages 3059-3069.
Crossref
Crossref
Wei Liu, Zhiheng Yu, Ziyu Wang, Emmanuelle L. Waubant, Suodi Zhai & Leslie Z. Benet. (2022) Using an animal model to predict the effective human dose for oral multiple sclerosis drugs. Clinical and Translational Science 16:3, pages 467-477.
Crossref
Crossref
Alireza Emadi, Sara Halakoo, Cyrus Taghizadeh Delkhoush & Fatemeh Ehsani. (2023) The Effects of Neuromodulators on Spasticity, Balance, and Gait in Patients with MS: A Systematic Review and Meta-Analysis Study. European Neurology 86:2, pages 144-154.
Crossref
Crossref
Hyejin Park & Qiu Wang. (2022)
State-of-the-art accounts of hyperpolarized
15
N-labeled molecular imaging probes for magnetic resonance spectroscopy and imaging
. Chemical Science 13:25, pages 7378-7391.
Crossref
Crossref
Melissa L. D. Rayner, Jess Healy & James B. Phillips. 2022. Peripheral Nerve Tissue Engineering and Regeneration. Peripheral Nerve Tissue Engineering and Regeneration
437
463
.
Sepehr Mamoei, Henrik Boye Jensen, Andreas Kristian Pedersen, Mikkel Karl Emil Nygaard, Simon Fristed Eskildsen, Ulrik Dalgas & Egon Stenager. (2021) Clinical, Neurophysiological, and MRI Markers of Fampridine Responsiveness in Multiple Sclerosis—An Explorative Study. Frontiers in Neurology 12.
Crossref
Crossref
Laura Marincaș, Graziella Liana Turdean, Monica Toșa, Zsolt Kovács, Béla Kovács, Réka Barabás, Noémi-Izabella Farkas & Liliana Bizo. (2021) Hydroxyapatite and Silicon-Modified Hydroxyapatite as Drug Carriers for 4-Aminopyridine. Crystals 11:9, pages 1124.
Crossref
Crossref
Murat Toraman, Semra Külekçi Öztürk, Berna Uslu Coşkun & Pembegül Güneş. (2020) The effects of 4-aminopyridine and methylprednisolone on recovery of the facial nerve crush injury. European Archives of Oto-Rhino-Laryngology 278:8, pages 3057-3063.
Crossref
Crossref
Ahmed S. Fayed, Nada S. Ayish, Badr A. El-Zeany & Hoda M. Marzouk. (2021) Novel dalfampridine-selective green potentiometric membrane sensors for in-line dissolution profiling of its extended release tablets. Microchemical Journal 165, pages 106127.
Crossref
Crossref
Nikita V. Chukanov, Oleg G. Salnikov, Ivan A. Trofimov, Mohammad S. H. Kabir, Kirill V. Kovtunov, Igor V. Koptyug & Eduard Y. Chekmenev. (2021)
Synthesis and
15
N NMR Signal Amplification by Reversible Exchange of [
15
N]Dalfampridine at Microtesla Magnetic Fields
. ChemPhysChem 22:10, pages 960-967.
Crossref
Crossref
Claudio Pizzolato, Mehmet A. Gunduz, Dinesh Palipana, Jingnan Wu, Gary Grant, Susan Hall, Rachel Dennison, Ross D. Zafonte, David G. Lloyd & Yang D. Teng. (2021) Non-invasive approaches to functional recovery after spinal cord injury: Therapeutic targets and multimodal device interventions. Experimental Neurology 339, pages 113612.
Crossref
Crossref
Dimos D. Mitsikostas, Triantafyllos Doskas, Stylianos Gkatzonis, Nikolaos Fakas, Maria Maltezou, Dimitrios Papadopoulos, Rania Gourgioti & Panayiotis Mitsias. (2021) A Prospective, Observational, Cohort Study to Assess the Efficacy and Safety of Prolonged-Release Fampridine in Cognition, Fatigue, Depression, and Quality of Life in Multiple Sclerosis Patients: The FAMILY Study. Advances in Therapy 38:3, pages 1536-1551.
Crossref
Crossref
Denis A. Baird, Jimmy Z. Liu, Jie Zheng, Solveig K. Sieberts, Thanneer Perumal, Benjamin Elsworth, Tom G. Richardson, Chia-Yen Chen, Minerva M. Carrasquillo, Mariet Allen, Joseph S. Reddy, Philip L. De Jager, Nilufer Ertekin-Taner, Lara M. Mangravite, Ben Logsdon, Karol Estrada, Philip C. Haycock, Gibran Hemani, Heiko Runz, George Davey Smith & Tom R. Gaunt. (2021) Identifying drug targets for neurological and psychiatric disease via genetics and the brain transcriptome. PLOS Genetics 17:1, pages e1009224.
Crossref
Crossref
Nazia Siddiqui & Saleem Javed. (2021) Quantum computational, spectroscopic investigations on ampyra (4-aminopyridine) by dft/td-dft with different solvents and molecular docking studies. Journal of Molecular Structure 1224, pages 129021.
Crossref
Crossref
Eva Costa Arpín. (2020) Efficacy and safety of fampridine for walking disability in multiple sclerosis. Neurodegenerative Disease Management 10:5, pages 277-287.
Crossref
Crossref
Kerstin Göbel & Heinz Wiendl. (2020) 4-aminopyridine is not just a symptomatic therapy, it has a neuroprotective effect – No. Multiple Sclerosis Journal 26:11, pages 1311-1312.
Crossref
Crossref
Stephen J. Page, Scott E. Kasner, Marcia Bockbrader, Mark Goldstein, Seth P. Finklestein, MingMing Ning, Waleed H. El-Feky, Christina A. Wilson & Holly Roberts. (2020) A double-blind, randomized, controlled study of two dose strengths of dalfampridine extended release on walking deficits in ischemic stroke. Restorative Neurology and Neuroscience 38:4, pages 301-309.
Crossref
Crossref
Aiko K. Thompson & Thomas Sinkjær. (2020) Can Operant Conditioning of EMG-Evoked Responses Help to Target Corticospinal Plasticity for Improving Motor Function in People With Multiple Sclerosis?. Frontiers in Neurology 11.
Crossref
Crossref
Cassandra Sampaio-Baptista, Astrid Vallès, Alexandre A. Khrapitchev, Guus Akkermans, Anderson M. Winkler, Sean Foxley, Nicola R. Sibson, Mark Roberts, Karla Miller, Mathew E. Diamond, Gerard J.M. Martens, Peter De Weerd & Heidi Johansen-Berg. (2020) White matter structure and myelin-related gene expression alterations with experience in adult rats. Progress in Neurobiology 187, pages 101770.
Crossref
Crossref
M. L. D. Rayner, J. Healy & J. B. Phillips. 2020. Peripheral Nerve Tissue Engineering and Regeneration. Peripheral Nerve Tissue Engineering and Regeneration
1
27
.
Nicole Pukos, Matthew T. Goodus, Fatma R. Sahinkaya & Dana M. McTigue. (2019) Myelin status and oligodendrocyte lineage cells over time after spinal cord injury: What do we know and what still needs to be unwrapped?. Glia 67:11, pages 2178-2202.
Crossref
Crossref
Ivan V. Skovpin, Alexandra Svyatova, Nikita Chukanov, Eduard Y. Chekmenev, Kirill V. Kovtunov & Igor V. Koptyug. (2019)
15
N Hyperpolarization of Dalfampridine at Natural Abundance for Magnetic Resonance Imaging
. Chemistry – A European Journal 25:55, pages 12694-12697.
Crossref
Crossref
Sanwang Li, Filip Cuyckens, Frederic Lynen & Frank Vanhaecke. (2019) Development of a method for the quantitative metabolite profiling of pharmaceutical drugs using HPLC-ICP-MS following pre-column derivatization of their amino and hydroxyl groups using 4-aminopyridine as a model compound. Journal of Analytical Atomic Spectrometry 34:4, pages 708-715.
Crossref
Crossref
Francesco Bolzoni, Roberto Esposti, Elzbieta Jankowska & Ingela Hammar. (2019) Interactions Between Baclofen and DC-induced Plasticity of Afferent Fibers within the Spinal Cord. Neuroscience 404, pages 119-129.
Crossref
Crossref
L. Filli, J. Werner, G. Beyer, K. Reuter, J. A. Petersen, M. Weller, B. Zörner & M. Linnebank. (2019) Predicting responsiveness to fampridine in gait-impaired patients with multiple sclerosis. European Journal of Neurology 26:2, pages 281-289.
Crossref
Crossref
Jeremy Hobart, Tjalf Ziemssen, Peter Feys, Michael Linnebank, Andrew D. Goodman, Rachel Farrell, Raymond Hupperts, Andrew R. Blight, Veronica Englishby, Manjit McNeill, Ih Chang, Gabriel Lima & Jacob Elkins. (2018) Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine. CNS Drugs 33:1, pages 61-79.
Crossref
Crossref
C. Bakirtzis, E. Konstantinopoulou, D.W. Langdon, E. Grigoriadou, F. Minti, I. Nikolaidis, M.K. Boziki, T. Tatsi, P. Ioannidis, T. Karapanayiotides, T. Afrantou, G. Hadjigeorgiou & N. Grigoriadis. (2018) Long-term effects of prolonged-release fampridine in cognitive function, fatigue, mood and quality of life of MS patients: The IGNITE study. Journal of the Neurological Sciences 395, pages 106-112.
Crossref
Crossref
Bryan D. Loy, Brett W. Fling, Fay B. Horak, Dennis N. Bourdette & Rebecca I. Spain. (2018) Effects of lipoic acid on walking performance, gait, and balance in secondary progressive multiple sclerosis. Complementary Therapies in Medicine 41, pages 169-174.
Crossref
Crossref
Ankit Tandon, Sangh Jyoti Singh & Rajnish Kumar Chaturvedi. (2018) Stem Cells as Potential Targets of Polyphenols in Multiple Sclerosis and Alzheimer’s Disease. BioMed Research International 2018, pages 1-30.
Crossref
Crossref
Sylvia Klineova, Rebecca Farber, Joshua Friedman, Colleen Farrell, Fred D Lublin & Stephen Krieger. (2018) Objective and subjective measures of dalfampridine efficacy in clinical practice. Multiple Sclerosis Journal - Experimental, Translational and Clinical 4:3, pages 205521731878674.
Crossref
Crossref
Verena Isabell Leussink, Xavier Montalban & Hans-Peter Hartung. (2018) Restoring Axonal Function with 4-Aminopyridine: Clinical Efficacy in Multiple Sclerosis and Beyond. CNS Drugs 32:7, pages 637-651.
Crossref
Crossref
María Belén Marzal-Alfaro, María Luisa Martín Barbero, JoseM García Domínguez, Fernando Romero-Delgado, María Luisa Martínez Ginés, Ana Herranz & María Sanjurjo-Sáez. (2018) Impact of fampridine on quality of life: clinical benefit in real-world practice. European Journal of Hospital Pharmacy 25:3, pages 138-143.
Crossref
Crossref
Dominik Kaczmarek & Elzbieta Jankowska. (2018) DC-Evoked Modulation of Excitability of Myelinated Nerve Fibers and Their Terminal Branches; Differences in Sustained Effects of DC. Neuroscience 374, pages 236-249.
Crossref
Crossref
Philipp Albrecht, Ingrid Kristine Bjørnå, David Brassat, Rachel Farrell, Peter Feys, Jeremy Hobart, Raymond Hupperts, Michael Linnebank, Jožef Magdič, Celia Oreja-Guevara, Carlo Pozzilli, Antonio Vasco Salgado & Tjalf Ziemssen. (2018) Prolonged-release fampridine in multiple sclerosis: clinical data and real-world experience. Report of an expert meeting. Therapeutic Advances in Neurological Disorders 11, pages 175628641880324.
Crossref
Crossref
Mark L. Moster, Robert C. Sergott & Benjamin E. Leiby. (2017) Dalfampridine Treatment in Nonarteritic Anterior Ischemic Optic Neuropathy. Journal of Neuro-Ophthalmology 37:3, pages 348-349.
Crossref
Crossref
Hongwei Chu, Pin Sun, Jiahui Yin, Guangming Liu, Yiwei Wang, Pengyao Zhao, Yizhun Zhu, Xiaohan Yang, Tiezheng Zheng, Xuezhong Zhou, Weilin Jin & Changkai Sun. (2017) Integrated network analysis reveals potentially novel molecular mechanisms and therapeutic targets of refractory epilepsies. PLOS ONE 12:4, pages e0174964.
Crossref
Crossref
Y.A. Kulkarni, M.S. Garud, M.J. Oza & A.B. Gaikwad. 2017. Nutrition and Lifestyle in Neurological Autoimmune Diseases. Nutrition and Lifestyle in Neurological Autoimmune Diseases
275
284
.
T.G. Murali Dhar & A.J. Dyckman. 2017. Comprehensive Medicinal Chemistry III. Comprehensive Medicinal Chemistry III
395
419
.
Melanie Korsen, Rhina Kunz, Ulf Schminke, Uwe Runge, Thomas Kohlmann & Alexander Dressel. (2017) Dalfampridine effects on cognition, fatigue, and dexterity. Brain and Behavior 7:1, pages e00559.
Crossref
Crossref
Kuang‐Ching Tseng, Haiyan Li, Andrew Clark, Leigh Sundem, Michael Zuscik, Mark Noble & John Elfar. (2016) 4‐Aminopyridine promotes functional recovery and remyelination in acute peripheral nerve injury. EMBO Molecular Medicine 8:12, pages 1409-1420.
Crossref
Crossref
L. Brambilla, D. Rossi Sebastiano, D. Aquino, V. Torri Clerici, G. Brenna, M. Moscatelli, R. Frangiamore, A.M. Giovannetti, C. Antozzi, R. Mantegazza, S. Franceschetti, M.G. Bruzzone, A. Erbetta & P. Confalonieri. (2016) Early effect of dalfampridine in patients with MS: A multi-instrumental approach to better investigate responsiveness. Journal of the Neurological Sciences 368, pages 402-407.
Crossref
Crossref
Sylvia Klineova, Rebecca Farber, Catarina Saiote, Colleen Farrell, Bradley N Delman, Lawrence N Tanenbaum, Joshua Friedman, Matilde Inglese, Fred D Lublin & Stephen Krieger. (2016) Relationship between timed 25-foot walk and diffusion tensor imaging in multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical 2, pages 205521731665536.
Crossref
Crossref
Angela Applebee, Andrew D. Goodman, Angeli S. Mayadev, Francois Bethoux, Myla D. Goldman, Michael Klingler, Andrew R. Blight & Enrique J. Carrazana. (2015) Effects of Dalfampridine Extended-release Tablets on 6-minute Walk Distance in Patients With Multiple Sclerosis: A Post Hoc Analysis of a Double-blind, Placebo-controlled Trial. Clinical Therapeutics 37:12, pages 2780-2787.
Crossref
Crossref
Katja Pavsic, Katarina Pelicon, Alenka Horvat Ledinek & Sasa Sega. (2015) Short-term impact of fampridine on motor and cognitive functions, mood and quality of life among multiple sclerosis patients. Clinical Neurology and Neurosurgery 139, pages 35-40.
Crossref
Crossref
Cecilie Fjeldstad, Gustavo Suárez, Michael Klingler, Herbert R. HenneyIIIIII, Adrian L. Rabinowicz & Gabriel Pardo. (2015) Dalfampridine Effects Beyond Walking Speed in Multiple Sclerosis. International Journal of MS Care 17:6, pages 275-283.
Crossref
Crossref
Andrew D Goodman, Francois Bethoux, Theodore R Brown, Randall T Schapiro, Ron Cohen, Lawrence N Marinucci, Herbert R HenneyIIIIII, Andrew R Blight, M Agius, BGW Arnason, FA Bethoux, CT BeverJrJr, JD Bowen, TR Brown, DW Dietrich, K Edwards, MS Freedman, M Freedman, NJ Kachuck, MD Kaufman, M Keilson, O Khan, LB Krupp, TP Leist, JW Lindsey, FD Lublin, MK Mass, D Mattson, D McGowan, R Naismith, C O’Connell, JJ Oger, H Panitch, MA Picone, KW Rammohan, RT Schapiro, SR Schwid, T Scott, C Short, BW Thrower, TL Vollmer, A Camac, JA Cooper, WF Chumley, A Cross, RT Dunnigan, JS Gitt, M Hillen, DR Jeffrey, BO Khatri, K Kresa-Reahl, S Moon, J Preiningerova, M Tullman, B Weinstock-Guttman & DR Wynn. (2015) Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials. Multiple Sclerosis Journal 21:10, pages 1322-1331.
Crossref
Crossref
Katja Schmitz, Julia Barthelmes, Leonie Stolz, Susanne Beyer, Olaf Diehl & Irmgard Tegeder. (2015) “Disease modifying nutricals” for multiple sclerosis. Pharmacology & Therapeutics 148, pages 85-113.
Crossref
Crossref
Cindy C. Lu, Xiao-Jie Cao, Samantha Wright, Le Ma, Donata Oertel & Lisa V. Goodrich. (2014) Mutation of Npr2 Leads to Blurred Tonotopic Organization of Central Auditory Circuits in Mice. PLoS Genetics 10:12, pages e1004823.
Crossref
Crossref
Andrew R. Blight, Herbert R. HenneyIIIIII & Ron Cohen. (2014) Development of dalfampridine, a novel pharmacologic approach for treating walking impairment in multiple sclerosis. Annals of the New York Academy of Sciences 1329:1, pages 33-44.
Crossref
Crossref
Gary BirnbaumJane Iverson. (2014) Dalfampridine may activate latent trigeminal neuralgia in patients with multiple sclerosis. Neurology 83:18, pages 1610-1612.
Crossref
Crossref
Andrew D. Goodman, Theodore R. Brown, Randall T. Schapiro, Michael Klingler, Ron Cohen & Andrew R. Blight. (2014) A Pooled Analysis of Two Phase 3 Clinical Trials of Dalfampridine in Patients with Multiple Sclerosis. International Journal of MS Care 16:3, pages 153-160.
Crossref
Crossref
Attila Kun, György Seprényi, András Varró, Julius Gy. Papp & János Pataricza. (2014) Neurogenic Contraction Induced by the Antiarrhythmic Compound, AVE 0118, in Rat Small Mesenteric Arteries. Basic & Clinical Pharmacology & Toxicology 115:4, pages 315-320.
Crossref
Crossref
Manuel A. Friese, Benjamin Schattling & Lars Fugger. (2014) Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis. Nature Reviews Neurology 10:4, pages 225-238.
Crossref
Crossref
María Teresa Frejo, Javier del Pino, Margarita Lobo, Jimena García, Miguel Andrés Capo & María Jesús Díaz. (2014) Liver and kidney damage induced by 4-aminopyridine in a repeated dose (28 days) oral toxicity study in rats: Gene expression profile of hybrid cell death. Toxicology Letters 225:2, pages 252-263.
Crossref
Crossref
T. Ruck, S. Bittner, O.J. Simon, K. Göbel, H. Wiendl, M. Schilling & S.G. Meuth. (2014) Long-term effects of dalfampridine in patients with multiple sclerosis. Journal of the Neurological Sciences 337:1-2, pages 18-24.
Crossref
Crossref
Emil Samara, Peter Winkle, Patricia Pardo, Herbert R. HenneyIIIIII, Susan L. Way, Eppie Brown, Angela Lee & Andrew R. Blight. (2013) Pharmacokinetics of dalfampridine extended release 7.5‐mg tablets in healthy subjects and individuals with mild and moderate renal impairment: An open‐label study. The Journal of Clinical Pharmacology 54:1, pages 53-60.
Crossref
Crossref
Kerstin Göbel, Jan-Hendrik Wedell, Alexander M. Herrmann, Lydia Wachsmuth, Susann Pankratz, Stefan Bittner, Thomas Budde, Christoph Kleinschnitz, Cornelius Faber, Heinz Wiendl & Sven G. Meuth. (2013) 4-Aminopyridine ameliorates mobility but not disease course in an animal model of multiple sclerosis. Experimental Neurology 248, pages 62-71.
Crossref
Crossref
Stefan Bittner & Sven G. Meuth. (2013) Targeting ion channels for the treatment of autoimmune neuroinflammation. Therapeutic Advances in Neurological Disorders 6:5, pages 322-336.
Crossref
Crossref
Snezana Maljevic & Holger Lerche. (2012) Potassium channels: a review of broadening therapeutic possibilities for neurological diseases. Journal of Neurology 260:9, pages 2201-2211.
Crossref
Crossref
Mihai Moldovan, Susana Alvarez, Mette Romer Rosberg & Christian Krarup. (2013) Axonal voltage-gated ion channels as pharmacological targets for pain. European Journal of Pharmacology 708:1-3, pages 105-112.
Crossref
Crossref
Stephan Schmidt. (2012) Fampridine improves severe dysarthria in secondary-progressive multiple sclerosis. Multiple Sclerosis Journal 19:4, pages 511-511.
Crossref
Crossref
Alexander K. OmmayaKenneth M. AdamsRichard M. AllmanEileen G. CollinsRory A. CooperC. Edward DixonPaul S. FishmanJames A. HenryRandy KardonRobert D. KernsJoel KupersmithAlbert LoRichard MackoRachel McArdleRegina E. McGlincheyMalcolm R. McNeilThomas P. O'TooleP. Hunter PeckhamMark H. TuszynskiStephen G. WaxmanGeorge F. Wittenberg. (2013) Opportunities in rehabilitation research. Journal of Rehabilitation Research and Development 50:6, pages vii-xxxii.
Crossref
Crossref
Andrew M. King, Nathan B. Menke, Kenneth D. Katz & Anthony F. Pizon. (2012) 4-Aminopyridine Toxicity: a Case Report and Review of the Literature. Journal of Medical Toxicology 8:3, pages 314-321.
Crossref
Crossref
Theodore E Pikoulas & Matthew A Fuller. (2012) Dalfampridine: A Medication to Improve Walking in Patients with Multiple Sclerosis. Annals of Pharmacotherapy 46:7-8, pages 1010-1015.
Crossref
Crossref
Carrie Hersh & Alex Rae-Grant. (2012) Extended-release dalfampridine in the management of multiple-sclerosis-related walking impairment. Therapeutic Advances in Neurological Disorders 5:4, pages 199-204.
Crossref
Crossref